RenovoRx Inc., a company listed on NASDAQ under the ticker symbol RNXT, has released an investor presentation detailing its latest advancements. The company is developing combination therapies utilizing its proprietary Trans-Arterial Micro-Perfusion (TAMP) platform. This includes the RenovoCath device, which has received FDA Orphan Drug Designation for its combination with the drug Gemcitabine in treating pancreatic and bile duct cancers. RenovoRx has initiated the commercialization of the FDA-cleared RenovoCath, with revenues in the first half of 2025 surpassing expectations. The company is advancing a pivotal Phase III TIGeR-PaC study for treating locally advanced pancreatic cancer, observing increased overall survival and progression-free survival, and a 65% reduction in adverse effects in the first interim analysis. The study's completion is anticipated by late 2025 or early 2026. RenovoRx is pursuing a potential peak annual U.S. revenue opportunity of approximately $400 million for RenovoCath as a stand-alone device. The company is led by an experienced leadership team and board of directors with expertise in clinical development and commercial execution in pharma, medical device, and combination therapy companies. You can access the full presentation through the link below.